Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioVersys AG

www.bioversys.com

Latest From BioVersys AG

Deal Watch: Troubled Antibiotics Maker Cempra Exploring Strategic Options

North Carolina biotech may need to conduct a 9,000-patient safety study after solithromycin was rejected by FDA, but it has $231m in cash and another Phase III candidate. Apricus is clearing financial room by transferring ex-US rights to Vivaros to Ferring, while Heat is acquiring former spinout Pelican.

Deals M & A

Start-Up Previews, September 2013

This Month's Profile Group: Central Venous Access: Start-Ups Change The Standard Of Care, features profiles of Bio 2 Medical, Houston Medical Robotics, and Mirador Biomedical. Plus these Start-Ups Across Health Care: BioVerys, Clinmet, Eclipse Breast Health Technologies, and Sea Lane Biotechnologies.

BioPharmaceutical Medical Device

BioVersys AG

Bacteria continue proving themselves immensely capable of resisting formerly effective antibiotics, and likewise capable of thwarting drugmakers’ efforts to create new types of compounds. The founders of BioVersys AG believe they can identify compounds uniquely able to block certain bacterial resistance factors; they aim to develop such molecules as adjuvants to be given in combination with existing antibiotics, to help restore their potency.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • BioVersys AG
  • Senior Management
  • Marc Gitzinger, PhD, CEO
    Marcel Tigges, PhD, CSO
  • Contact Info
  • BioVersys AG
    Phone: 61 -633 -2250
    Hochbergerstrasse 60c
    3rd. Fl.
    Basel, CH-4057
    Switzerland
UsernamePublicRestriction

Register